|
G |
Adra1b |
adrenoceptor alpha 1B |
multiple interactions |
EXP |
4-Aminopyridine inhibits the reaction [ADRA1B protein results in increased susceptibility to Phenylephrine] |
CTD |
PMID:18480251 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
4-Aminopyridine results in increased expression of BAX mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
EXP |
4-Aminopyridine results in decreased expression of BIRC2 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
EXP |
4-Aminopyridine results in decreased expression of BIRC3 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Bmf |
Bcl2 modifying factor |
increases expression |
EXP |
4-Aminopyridine results in increased expression of BMF mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 3:110,303,515...110,324,125
Ensembl chr 3:110,306,067...110,324,084
|
|
G |
Casp3 |
caspase 3 |
increases activity |
EXP |
4-Aminopyridine results in increased activity of CASP3 protein |
CTD |
PMID:24378259 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity |
EXP |
4-Aminopyridine results in increased activity of CASP7 protein |
CTD |
PMID:24378259 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp9 |
caspase 9 |
increases activity |
EXP |
4-Aminopyridine results in increased activity of CASP9 protein |
CTD |
PMID:24378259 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cd40 |
CD40 molecule |
increases expression |
EXP |
4-Aminopyridine results in increased expression of CD40 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd40lg |
CD40 ligand |
increases expression |
EXP |
4-Aminopyridine results in increased expression of CD40LG mRNA |
CTD |
PMID:24378259 |
|
NCBI chr X:159,703,703...159,714,886
Ensembl chr X:159,703,578...159,716,562
|
|
G |
Ctsb |
cathepsin B |
increases expression |
EXP |
4-Aminopyridine results in increased expression of CTSB mRNA |
CTD |
PMID:24378259 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
increases expression |
EXP |
4-Aminopyridine results in increased expression of DPYSL4 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 1:211,423,022...211,438,533
Ensembl chr 1:211,423,022...211,438,531
|
|
G |
Gad2 |
glutamate decarboxylase 2 |
increases expression multiple interactions |
EXP |
4-Aminopyridine results in increased expression of GAD2 mRNA KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of GAD2 mRNA] |
CTD |
PMID:25917026 |
|
NCBI chr17:89,171,576...89,234,770
Ensembl chr17:89,171,250...89,238,040
|
|
G |
Galnt5 |
polypeptide N-acetylgalactosaminyltransferase 5 |
decreases expression |
EXP |
4-Aminopyridine results in decreased expression of GALNT5 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 3:44,025,964...44,072,073
Ensembl chr 3:44,025,300...44,074,678
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
multiple interactions |
ISO |
[Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein |
CTD |
PMID:19911010 |
|
NCBI chr 1:101,819,068...101,859,146
Ensembl chr 1:101,820,461...101,856,881
|
|
G |
Hdac5 |
histone deacetylase 5 |
multiple interactions |
EXP |
[Bicuculline co-treated with 4-Aminopyridine] affects the localization of HDAC5 protein |
CTD |
PMID:15773917 |
|
NCBI chr10:90,140,183...90,169,853
Ensembl chr10:90,140,183...90,151,042
|
|
G |
Jph3 |
junctophilin 3 |
increases expression |
EXP |
4-Aminopyridine results in increased expression of JPH3 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr19:54,553,419...54,613,477
Ensembl chr19:54,553,419...54,613,477
|
|
G |
Kcna10 |
potassium voltage-gated channel subfamily A member 10 |
multiple interactions |
ISO |
4-Aminopyridine inhibits the reaction [KCNA10 protein results in increased transport of Potassium] |
CTD |
PMID:10836990 |
|
NCBI chr 2:209,920,590...209,932,665
Ensembl chr 2:209,920,590...209,932,665
|
|
G |
Kcnd3 |
potassium voltage-gated channel subfamily D member 3 |
increases expression multiple interactions |
EXP |
4-Aminopyridine results in increased expression of KCND3 mRNA KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of KCND3 mRNA] |
CTD |
PMID:25917026 |
|
NCBI chr 2:207,923,775...208,140,727
Ensembl chr 2:207,923,775...208,140,727
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
4-Aminopyridine results in decreased activity of KCNH2 protein |
CTD |
PMID:19915712 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kcnip1 |
potassium voltage-gated channel interacting protein 1 |
decreases expression increases expression multiple interactions |
EXP |
4-Aminopyridine results in decreased expression of KCNIP1 mRNA 4-Aminopyridine results in increased expression of KCNIP1 mRNA KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased abundance of gamma-Aminobutyric Acid]; KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of GAD2 mRNA]; KCNIP1 mRNA promotes the reaction [4-Aminopyridine results in increased expression of KCND3 mRNA] |
CTD |
PMID:24378259 PMID:25917026 |
|
NCBI chr10:18,558,128...18,942,677
Ensembl chr10:18,558,128...18,942,540
|
|
G |
Mag |
myelin-associated glycoprotein |
decreases expression |
EXP |
4-Aminopyridine results in decreased expression of MAG mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 1:89,345,325...89,360,905
Ensembl chr 1:89,345,429...89,360,733
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
increases expression |
EXP |
4-Aminopyridine results in increased expression of MAP1LC3A mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 3:150,801,289...150,802,935
Ensembl chr 3:150,801,289...150,802,935
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK1 protein] 4-Aminopyridine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; ciproxifan inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein]; hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19911010 PMID:22759588 PMID:28132918 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] results in increased activity of and results in increased phosphorylation of MAPK3 protein] 4-Aminopyridine results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; ciproxifan inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein]; hispidulin inhibits the reaction [4-Aminopyridine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19911010 PMID:22759588 PMID:28132918 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; [Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] affects the localization of NCOR2 protein] |
CTD |
PMID:15773917 |
|
NCBI chr12:36,871,917...37,033,701
Ensembl chr12:36,871,999...37,033,701
|
|
G |
Olr1583 |
olfactory receptor 1583 |
decreases expression |
EXP |
4-Aminopyridine results in decreased expression of OLR1583 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr13:91,725,324...91,726,265
Ensembl chr13:91,725,324...91,726,265
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
EXP |
[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]; Dizocilpine Maleate inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; KN 62 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]]; STO 609 inhibits the reaction [[Bicuculline co-treated with 4-Aminopyridine] promotes the reaction [alitretinoin results in increased activity of RARA protein]] |
CTD |
PMID:15773917 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
RGD1311517 |
similar to RIKEN cDNA 9430015G10 |
increases expression |
EXP |
4-Aminopyridine results in increased expression of C1ORF159 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 5:173,542,058...173,559,761
Ensembl chr 5:173,542,358...173,559,761
|
|
G |
S100a7a |
S100 calcium binding protein A7A |
decreases expression |
EXP |
4-Aminopyridine results in decreased expression of S100A7A mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 2:190,058,093...190,063,132
Ensembl chr 2:190,058,093...190,062,534
|
|
G |
Syn1 |
synapsin I |
affects response to substance multiple interactions increases response to substance increases expression |
ISO EXP |
SYN1 protein affects the susceptibility to 4-Aminopyridine ciproxifan inhibits the reaction [4-Aminopyridine results in increased expression of SYN1 protein modified form] SYN1 results in increased susceptibility to 4-Aminopyridine |
CTD |
PMID:22759588 PMID:28132918 |
|
NCBI chr X:1,321,315...1,379,202
Ensembl chr X:1,321,315...1,379,198
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
increases expression |
EXP |
4-Aminopyridine results in increased expression of TRAF2 mRNA |
CTD |
PMID:24378259 |
|
NCBI chr 3:2,746,061...2,770,690
Ensembl chr 3:2,746,075...2,770,620
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
[barium chloride results in increased abundance of Barium] which results in decreased activity of ACHE protein |
CTD |
PMID:31407482 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Alb |
albumin |
multiple interactions increases secretion |
EXP |
Plant Extracts inhibits the reaction [barium chloride results in increased secretion of ALB protein] |
CTD |
PMID:26732703 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
EXP |
[barium chloride results in increased abundance of Barium] which results in decreased activity of CAT protein; Plant Extracts inhibits the reaction [barium chloride results in decreased activity of CAT protein] |
CTD |
PMID:26732703 PMID:31407482 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP |
barium chloride results in increased expression of IL1B mRNA Plant Extracts inhibits the reaction [barium chloride results in increased expression of IL1B mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
EXP |
barium chloride results in increased expression of IL6 mRNA [barium chloride results in increased abundance of Barium] which results in increased expression of IL6 protein; Plant Extracts inhibits the reaction [barium chloride results in increased expression of IL6 mRNA] |
CTD |
PMID:26732703 PMID:31407482 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kcne1 |
potassium voltage-gated channel subfamily E regulatory subunit 1 |
multiple interactions |
ISO |
barium chloride results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16909339 |
|
NCBI chr11:32,498,260...32,511,202
Ensembl chr11:32,498,261...32,508,420
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
multiple interactions |
EXP |
barium chloride inhibits the reaction [KCNJ2 protein results in increased transport of Potassium] |
CTD |
PMID:11087224 |
|
NCBI chr10:99,429,337...99,442,520
Ensembl chr10:99,437,436...99,439,114
|
|
G |
Kcnk3 |
potassium two pore domain channel subfamily K member 3 |
decreases activity |
EXP |
barium chloride results in decreased activity of KCNK3 protein |
CTD |
PMID:16020457 |
|
NCBI chr 6:27,154,274...27,190,209
Ensembl chr 6:27,151,612...27,190,132
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
multiple interactions |
ISO |
barium chloride results in decreased activity of [KCNQ1 protein binds to KCNE1 protein] |
CTD |
PMID:16909339 |
|
NCBI chr 1:216,293,087...216,630,339
Ensembl chr 1:216,293,087...216,630,339
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
EXP |
barium chloride results in increased expression of MT1 mRNA Plant Extracts inhibits the reaction [barium chloride results in increased expression of MT1 mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
increases expression multiple interactions |
EXP |
barium chloride results in increased expression of MT2A mRNA Plant Extracts inhibits the reaction [barium chloride results in increased expression of MT2A mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Serpine1 |
serpin family E member 1 |
increases secretion |
EXP |
barium chloride results in increased secretion of SERPINE1 protein |
CTD |
PMID:21596853 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression multiple interactions |
EXP |
barium chloride results in decreased expression of SOD2 mRNA Plant Extracts inhibits the reaction [barium chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Stx1a |
syntaxin 1A |
multiple interactions affects localization |
EXP |
Propofol inhibits the reaction [barium chloride affects the localization of STX1A protein]; STX1A protein modified form inhibits the reaction [Propofol inhibits the reaction [barium chloride affects the localization of STX1A protein]] |
CTD |
PMID:29320738 |
|
NCBI chr12:24,682,050...24,710,002
Ensembl chr12:24,682,041...24,710,019
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
Plant Extracts inhibits the reaction [barium chloride results in increased expression of TNF mRNA] |
CTD |
PMID:26732703 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tsc22d3 |
TSC22 domain family, member 3 |
multiple interactions |
ISO |
[barium chloride results in increased abundance of Barium] inhibits the reaction [Hydrocortisone results in increased expression of TSC22D3 mRNA] |
CTD |
PMID:29957541 |
|
NCBI chr X:111,884,285...111,944,693
Ensembl chr X:111,884,295...111,887,906
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
berberine increases expression of abca1 protein in mouse liver and human hepatocytes |
RGD |
PMID:29505790 |
RGD:19165131 |
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Berberine results in increased expression of ABCB1A mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
Berberine results in increased expression of ABCB1B mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589
|
|
G |
Acan |
aggrecan |
decreases expression |
ISO |
Berberine results in decreased expression of ACAN mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:140,762,758...140,824,441
Ensembl chr 1:140,762,758...140,824,441
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr10:104,724,534...104,748,003
Ensembl chr10:104,722,958...104,748,050
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
EXP |
Berberine results in decreased expression of ACTA2 protein |
CTD |
PMID:17973934 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity |
EXP ISO |
Berberine results in increased activity of AHR protein |
CTD |
PMID:16046213 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23954465 PMID:30138605 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein] |
CTD |
PMID:30138605 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Berberine results in decreased expression of AURKB mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
|
|
G |
Aurkc |
aurora kinase C |
increases expression |
ISO |
Berberine results in increased expression of AURKC mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:69,958,452...69,964,546
Ensembl chr 1:69,958,452...69,963,592
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BBC3 mRNA [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression increases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:23954465 PMID:24751971 PMID:25600690 PMID:26712469 PMID:30138605 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
Berberine results in decreased expression of BCL2L1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA Berberine results in increased expression of BCL2L11 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein] |
CTD |
PMID:26478571 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects binding |
ISO |
Berberine binds to BIRC5 promoter |
CTD |
PMID:17968851 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity increases expression |
ISO EXP |
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Berberine results in increased activity of CASP8 protein |
CTD |
PMID:20656010 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO EXP |
Berberine results in increased cleavage of CASP9 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein |
CTD |
PMID:16505103 PMID:26712469 PMID:30138605 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] |
CTD |
PMID:20828602 PMID:24751971 PMID:25600690 PMID:30138605 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] |
CTD |
PMID:16391493 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCNE1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccnt1 |
cyclin T1 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 7:140,215,052...140,245,958
Ensembl chr 7:140,219,551...140,245,723
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CD36 mRNA Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] |
CTD |
PMID:28038998 PMID:29408570 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDH2 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr18:8,146,971...8,366,037
Ensembl chr18:8,146,971...8,360,684
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK4 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK6 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 3:11,742,269...11,747,117
Ensembl chr 3:11,742,266...11,747,113
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Berberine results in increased expression of CDKN1A protein |
CTD |
PMID:16505103 PMID:23747414 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Berberine results in increased expression of CDKN1B protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Berberine results in increased expression of CDKN1C mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
affects phosphorylation multiple interactions increases expression |
ISO |
Berberine affects the phosphorylation of CEBPB protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CEBPB mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
Berberine results in increased expression of CHEK1 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
ISO |
Berberine results in increased expression of CHEK2 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL10A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr20:41,180,295...41,190,664
Ensembl chr20:41,184,287...41,189,633
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL1A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
decreases expression |
ISO |
Berberine results in decreased expression of COL2A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:139,454,945...139,484,403
Ensembl chr 7:139,455,242...139,483,997
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Berberine results in increased expression of CREBBP mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Berberine affects the localization of CYCS protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression multiple interactions |
ISO EXP |
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:16046213 PMID:22342832 PMID:24583342 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:22342832 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA] Berberine results in increased expression of CYP2B10 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B9 mRNA]; Berberine promotes the reaction [Streptozocin results in increased expression of CYP2B9 mRNA] Berberine results in increased expression of CYP2B9 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:22342832 PMID:25455889 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity multiple interactions decreases expression |
EXP ISO |
Berberine results in decreased activity of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein |
CTD |
PMID:21524698 PMID:30086269 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 1:248,952,896...248,956,579
Ensembl chr 1:248,895,738...248,898,607
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:21,922,515...21,968,495
Ensembl chr 8:21,922,515...21,968,495
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:149,131,541...149,170,061
Ensembl chr 3:149,131,785...149,208,786
|
|
G |
Dzip3 |
DAZ interacting zinc finger protein 3 |
increases expression |
ISO |
Berberine results in increased expression of DZIP3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:54,404,777...54,475,361
Ensembl chr11:54,404,446...54,472,447
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Berberine results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr16:68,954,860...68,968,248
Ensembl chr16:68,954,875...68,968,248
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Berberine results in increased expression of EP300 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression multiple interactions increases expression |
ISO |
Berberine results in decreased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA] |
CTD |
PMID:26478571 PMID:29408570 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein |
CTD |
PMID:20564506 PMID:20656010 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Berberine results in increased expression of FASLG mRNA; Berberine results in increased expression of FASLG protein |
CTD |
PMID:20656010 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:26712469 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein |
CTD |
PMID:26712469 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Gdf5 |
growth differentiation factor 5 |
decreases expression |
ISO |
Berberine results in decreased expression of GDF5 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 3:151,482,672...151,487,129
Ensembl chr 3:151,483,249...151,486,693
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein] |
CTD |
PMID:24751971 PMID:25455889 PMID:30138605 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of GPX1 mRNA] |
CTD |
PMID:24751971 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:20462044 PMID:23954465 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:24751971 PMID:25600690 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
H2ac12 |
H2A clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,527,990...44,528,557
Ensembl chr17:44,528,125...44,528,511
|
|
G |
H2ax |
H2A.X variant histone |
increases expression decreases expression multiple interactions |
ISO |
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] |
CTD |
PMID:23363784 PMID:23747414 PMID:27311644 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,527,421...44,527,801
Ensembl chr17:44,527,421...44,527,801
|
|
G |
H2bc9 |
H2B clustered histone 9 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,519,815...44,520,269
Ensembl chr17:44,519,860...44,520,240
|
|
G |
H3c1 |
H3 clustered histone 1 |
decreases expression |
ISO |
Berberine results in decreased expression of H3C1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:43,616,206...43,616,735
Ensembl chr17:44,839,721...44,840,131 Ensembl chr17:44,839,721...44,840,131 Ensembl chr17:44,839,721...44,840,131 Ensembl chr17:44,839,721...44,840,131
|
|
G |
H3f3a |
H3.3 histone A |
decreases expression |
ISO |
Berberine results in decreased expression of H3-3A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:99,091,246...99,102,828
Ensembl chr13:99,091,763...99,101,208
|
|
G |
H3f4 |
H3.4 histone |
decreases expression |
ISO |
Berberine results in decreased expression of H3-4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:45,304,696...45,305,106
|
|
G |
Hat1 |
histone acetyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of HAT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:58,022,395...58,070,067
Ensembl chr 3:58,022,238...58,070,068
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:43,084,870...43,108,198
Ensembl chr20:43,084,870...43,108,198
|
|
G |
Hdac5 |
histone deacetylase 5 |
increases expression |
ISO |
Berberine results in increased expression of HDAC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:90,140,183...90,169,853
Ensembl chr10:90,140,183...90,151,042
|
|
G |
Hdac8 |
histone deacetylase 8 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:72,163,777...72,370,058
Ensembl chr X:72,163,777...72,370,044
|
|
G |
Hdac9 |
histone deacetylase 9 |
decreases expression increases expression |
ISO |
Berberine results in decreased expression of HDAC9 mRNA Berberine results in increased expression of HDAC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:53,487,367...54,358,694
Ensembl chr 6:53,488,883...54,059,119
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] |
CTD |
PMID:29408570 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:43,627,237...43,627,629
Ensembl chr17:43,627,237...43,627,629
|
|
G |
Hist1h2ah |
histone cluster 1 H2A family member H |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:43,632,354...43,632,851
Ensembl chr17:44,747,796...44,748,188 Ensembl chr17:44,747,796...44,748,188
|
|
G |
Hist1h2ak |
histone cluster 1, H2ak |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,840,990...44,841,382
Ensembl chr17:44,840,990...44,841,382
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,833,924...44,834,305
Ensembl chr17:44,833,924...44,834,305
|
|
G |
Hist1h2bl |
histone cluster 1 H2B family member l |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,748,445...44,748,910
Ensembl chr17:44,748,482...44,748,862
|
|
G |
Hist1h2bq |
histone cluster 1 H2B family member Q |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:43,679,925...43,689,311
Ensembl chr17:43,679,925...43,689,311
|
|
G |
Hist1h3b |
histone cluster 1, H3b |
decreases expression |
ISO |
Berberine results in decreased expression of H3C12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,760,023...44,764,058
Ensembl chr17:44,839,721...44,840,131 Ensembl chr17:44,839,721...44,840,131 Ensembl chr17:44,839,721...44,840,131 Ensembl chr17:44,839,721...44,840,131
|
|
G |
Hist1h4b |
histone cluster 1 H4 family member B |
decreases expression |
ISO |
Berberine results in decreased expression of H4C9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,522,144...44,526,587
Ensembl chr17:44,522,140...44,526,583
|
|
G |
Hist2h2aa3 |
histone cluster 2 H2A family member A3 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC18 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:198,388,766...198,389,293
Ensembl chr 2:198,388,809...198,389,201 Ensembl chr 2:198,388,809...198,389,201
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:198,360,837...198,363,399
Ensembl chr 2:198,360,998...198,361,378
|
|
G |
Hist2h4 |
histone cluster 2, H4 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:198,411,955...198,412,350
Ensembl chr 2:198,411,955...198,412,350
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of HMOX1 protein Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein] |
CTD |
PMID:23954465 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein] |
CTD |
PMID:18563319 PMID:25455889 |
|
NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
Berberine results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:59,164,601...59,183,899
Ensembl chr 8:59,164,572...59,183,908
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of IFNG mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein] Berberine results in increased expression of IGF1R protein |
CTD |
PMID:23954465 |
|
NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA Berberine results in increased expression of IL10 mRNA |
CTD |
PMID:21867779 PMID:30138605 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA] |
CTD |
PMID:16391493 PMID:29170048 PMID:30138605 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
Berberine results in increased expression of IL2 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein] |
CTD |
PMID:30240693 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein] Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein] |
CTD |
PMID:28916288 PMID:29170048 PMID:30138605 PMID:30240693 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Itga1 |
integrin subunit alpha 1 |
increases expression |
ISO |
Berberine results in increased expression of ITGA1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 2:47,127,403...47,281,387
Ensembl chr 2:47,127,219...47,281,421
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects localization multiple interactions |
EXP |
Berberine affects the localization of JUN protein arsenic trioxide promotes the reaction [Berberine affects the localization of JUN protein] |
CTD |
PMID:18294404 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
EXP |
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kdm1a |
lysine demethylase 1A |
increases expression |
ISO |
Berberine results in increased expression of KDM1A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:154,909,003...154,965,171
Ensembl chr 5:154,909,003...154,965,171
|
|
G |
Kdm4a |
lysine demethylase 4A |
increases expression |
ISO |
Berberine results in increased expression of KDM4A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:136,967,650...137,014,402
Ensembl chr 5:136,967,650...137,014,430
|
|
G |
Kdm5b |
lysine demethylase 5B |
increases expression |
ISO |
Berberine results in increased expression of KDM5B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:51,384,371...51,455,392
Ensembl chr13:51,384,389...51,455,357
|
|
G |
Kdm6a |
lysine demethylase 6A |
increases expression |
ISO |
Berberine results in increased expression of KDM6A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:4,805,493...4,945,788
Ensembl chr X:4,806,277...4,945,944
|
|
G |
Kdm6b |
lysine demethylase 6B |
increases expression |
ISO |
Berberine results in increased expression of KDM6B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:56,000,494...56,009,582
Ensembl chr10:56,001,799...56,008,885
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
increases expression |
ISO |
Berberine results in increased expression of KMT5A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:37,558,150...37,581,183
Ensembl chr12:37,559,770...37,574,750
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] |
CTD |
PMID:18640378 PMID:20564506 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
LOC100912489 |
histone H4-like |
decreases expression |
ISO |
Berberine results in decreased expression of H4C3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:170,144,871...170,145,311
Ensembl chr 4:170,144,951...170,145,262
|
|
G |
LOC103690190 |
histone H2A type 1-E |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:44,747,686...44,748,229
Ensembl chr17:44,747,796...44,748,188 Ensembl chr17:44,747,796...44,748,188
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
EXP |
Berberine results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:18294404 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA] |
CTD |
PMID:18294404 PMID:20462044 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of MCM2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 4:120,825,699...120,840,221
Ensembl chr 4:120,825,699...120,840,111
|
|
G |
Mir19a |
microRNA 19a |
decreases expression |
ISO |
Berberine results in decreased expression of MIR19A mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:100,180,162...100,180,243
Ensembl chr15:100,180,162...100,180,243
|
|
G |
Mir92a1 |
microRNA 92a-1 |
decreases expression |
ISO |
Berberine results in decreased expression of MIR92A1 mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:100,180,586...100,180,663
Ensembl chr15:100,180,586...100,180,663
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Berberine results in increased expression of MMP13 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP14 protein] |
CTD |
PMID:18294404 |
|
NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein] |
CTD |
PMID:18294404 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] |
CTD |
PMID:21963898 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of MTTP protein] |
CTD |
PMID:25455889 |
|
NCBI chr 2:243,366,181...243,407,608
Ensembl chr 2:243,366,181...243,407,608
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions affects localization |
EXP |
arsenic trioxide promotes the reaction [Berberine affects the localization of MYC protein] |
CTD |
PMID:18294404 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein] |
CTD |
PMID:26712469 |
|
NCBI chr 6:52,122,085...52,156,473
Ensembl chr 6:52,122,085...52,156,472
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression increases activity multiple interactions |
ISO EXP |
Berberine results in increased expression of NFE2L2 protein Berberine results in increased activity of NFE2L2 protein Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23523906 PMID:23954465 PMID:30818834 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:21963898 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23954465 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] |
CTD |
PMID:21095217 PMID:23523906 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
IEP |
Berberine reverses reaction [Carbontetrachloride decreases Nqo1 mRNA in liver] |
RGD |
PMID:31432116 |
RGD:25823187 |
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21524698 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Berberine results in increased activity of NR1I3 protein |
CTD |
PMID:30818834 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nsd2 |
nuclear receptor binding SET domain protein 2 |
decreases expression |
ISO |
Berberine results in decreased expression of NSD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:82,119,210...82,196,501
Ensembl chr14:82,119,210...82,171,480
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of ODC1 protein] |
CTD |
PMID:18294404 |
|
NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
|
|
G |
Omd |
osteomodulin |
increases expression |
ISO |
Berberine results in increased expression of OMD mRNA |
CTD |
PMID:26478571 |
|
NCBI chr17:15,476,100...15,484,324
Ensembl chr17:15,475,710...15,484,269
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:21320518 |
|
NCBI chr12:39,353,613...39,396,042
Ensembl chr12:39,353,613...39,396,042
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein |
CTD |
PMID:16505103 PMID:26712469 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases response to substance increases expression decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] PPARG mRNA results in increased susceptibility to Berberine Berberine results in increased expression of PPARG mRNA Berberine results in decreased expression of PPARG mRNA |
CTD |
PMID:20564506 PMID:26478571 PMID:29408570 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Prg4 |
proteoglycan 4 |
decreases expression |
ISO |
Berberine results in decreased expression of PRG4 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr13:67,672,588...67,688,902
Ensembl chr13:67,672,878...67,688,477
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation |
ISO |
Berberine results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:28298333 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein |
CTD |
PMID:18294404 |
|
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions decreases activity |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein |
CTD |
PMID:18294404 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of PRMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:100,971,132...100,980,411
Ensembl chr 1:100,971,273...100,980,340
|
|
G |
Prmt2 |
protein arginine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of PRMT2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:13,154,513...13,212,613
Ensembl chr20:13,156,241...13,212,606
|
|
G |
Prmt5 |
protein arginine methyltransferase 5 |
increases expression |
ISO |
Berberine results in increased expression of PRMT5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:33,156,508...33,165,893
Ensembl chr15:33,156,492...33,165,895
|
|
G |
Prmt6 |
protein arginine methyltransferase 6 |
increases expression |
ISO |
Berberine results in increased expression of PRMT6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:213,173,403...213,180,721
Ensembl chr 2:213,173,403...213,178,632 Ensembl chr 2:213,173,403...213,178,632
|
|
G |
Prmt7 |
protein arginine methyltransferase 7 |
increases expression |
ISO |
Berberine results in increased expression of PRMT7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:38,189,605...38,237,155
Ensembl chr19:38,189,605...38,237,308
|
|
G |
Prmt8 |
protein arginine methyltransferase 8 |
increases expression |
ISO |
Berberine results in increased expression of PRMT8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:160,253,409...160,334,647
Ensembl chr 4:160,253,073...160,334,910
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Berberine results in increased expression of PTEN protein |
CTD |
PMID:29408570 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] |
CTD |
PMID:21095217 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rbp4 |
retinol binding protein 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased secretion of RBP4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr 1:256,806,476...256,813,678
Ensembl chr 1:256,806,472...256,813,711
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] |
CTD |
PMID:23523906 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
RGD1562378 |
histone H4 variant H4-v.1 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C14 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:170,762,862...170,763,962
Ensembl chr 4:170,763,605...170,763,916
|
|
G |
Rln1 |
relaxin 1 |
affects binding increases expression multiple interactions |
EXP |
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA |
CTD |
PMID:22363579 |
|
NCBI chr 1:247,483,298...247,486,331
Ensembl chr 1:247,483,302...247,486,202
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Berberine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26478571 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
Setd1b |
SET domain containing 1B, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD1B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:38,843,167...38,869,180
Ensembl chr12:38,845,621...38,869,346
|
|
G |
Setd2 |
SET domain containing 2, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:118,802,478...118,888,224
Ensembl chr 8:118,803,075...118,888,224
|
|
G |
Setd3 |
SET domain containing 3, actin histidine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:132,023,128...132,090,072
Ensembl chr 6:132,023,945...132,075,875
|
|
G |
Setd5 |
SET domain containing 5 |
increases expression |
ISO |
Berberine results in increased expression of SETD5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:145,017,549...145,095,247
Ensembl chr 4:145,017,608...145,095,245
|
|
G |
Setd6 |
SET domain containing 6, protein lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:9,758,613...9,766,333
Ensembl chr19:9,762,489...9,765,484
|
|
G |
Setd7 |
SET domain containing 7, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:140,576,188...140,618,405
Ensembl chr 2:140,576,188...140,618,405
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of SETDB1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:196,495,867...196,527,412
Ensembl chr 2:196,495,867...196,527,127
|
|
G |
Setdb2 |
SET domain bifurcated histone lysine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of SETDB2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:38,699,135...39,745,035
Ensembl chr15:39,712,861...39,742,103 Ensembl chr15:39,712,861...39,742,103
|
|
G |
Si |
sucrase-isomaltase |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA] |
CTD |
PMID:20229011 |
|
NCBI chr 2:170,220,794...170,301,348
Ensembl chr 2:170,221,245...170,301,348
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein] |
CTD |
PMID:26712469 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein |
CTD |
PMID:26712469 |
|
NCBI chr 1:86,948,866...86,971,954
Ensembl chr 1:86,948,918...86,971,952
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions increases expression decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein |
CTD |
PMID:26712469 PMID:27311644 |
|
NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
decreases expression |
ISO |
Berberine results in decreased expression of SLC27A5 mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 1:65,576,599...65,587,192
Ensembl chr 1:65,576,535...65,587,186
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Slc6a19 |
solute carrier family 6 member 19 |
multiple interactions |
EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein] |
CTD |
PMID:21073932 |
|
NCBI chr 1:32,199,869...32,218,628
Ensembl chr 1:32,199,810...32,220,045
|
|
G |
Smyd3 |
SET and MYND domain containing 3 |
affects expression |
ISO |
Berberine affects the expression of SMYD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:97,330,120...97,807,813
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] |
CTD |
PMID:21095217 PMID:22775417 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:22775417 PMID:24751971 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
Berberine results in decreased expression of SOX9 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Berberine results in increased expression of SP7 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:143,957,316...143,967,488
Ensembl chr 7:143,958,858...143,967,484
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases expression |
ISO |
Berberine results in increased expression of SPARC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:40,742,390...40,764,232
Ensembl chr10:40,742,400...40,764,185
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity |
ISO |
Berberine results in decreased activity of TERT protein |
CTD |
PMID:25265580 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression multiple interactions |
EXP |
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] |
CTD |
PMID:17973934 PMID:23523906 PMID:30138605 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] |
CTD |
PMID:21963898 PMID:30240693 |
|
NCBI chr 5:82,587,424...82,601,056
Ensembl chr 5:82,587,420...82,601,052
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
ISO EXP |
Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:16391493 PMID:20656010 PMID:21095217 PMID:21867779 PMID:23523906 PMID:25600690 PMID:28533128 PMID:29170048 PMID:30240693 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
Berberine results in decreased activity of TOP1 protein |
CTD |
PMID:23747414 |
|
NCBI chr 3:156,635,688...156,717,686
Ensembl chr 3:156,642,464...156,717,686
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions affects response to substance |
ISO |
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine |
CTD |
PMID:23747414 |
|
NCBI chr10:86,901,467...86,930,947
Ensembl chr10:86,901,007...86,932,154
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein |
CTD |
PMID:20656010 PMID:26712469 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
Berberine results in increased expression of TRAF1 protein |
CTD |
PMID:20656010 |
|
NCBI chr 3:14,003,340...14,022,955
Ensembl chr 3:14,003,340...14,022,672
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 3:2,746,061...2,770,690
Ensembl chr 3:2,746,075...2,770,620
|
|
G |
Tstd1 |
thiosulfate sulfurtransferase like domain containing 1 |
increases expression |
ISO |
Berberine results in increased expression of TSTD1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:89,805,652...89,807,355
Ensembl chr13:89,805,962...89,807,243
|
|
G |
Ube2a |
ubiquitin-conjugating enzyme E2A |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:123,486,988...123,497,726
Ensembl chr X:123,486,989...123,497,726
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:37,439,947...37,454,867
Ensembl chr10:37,441,284...37,455,022
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of UCP2 mRNA] |
CTD |
PMID:28533128 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression |
ISO |
Berberine results in increased expression of VEGFC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr16:40,440,371...40,555,178
Ensembl chr16:40,440,207...40,555,576
|
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
dofetilide inhibits the reaction [Isoproterenol results in decreased expression of FKBP1B mRNA]; dofetilide inhibits the reaction [Isoproterenol results in decreased expression of FKBP1B protein] |
CTD |
PMID:20723002 |
|
NCBI chr 6:29,975,863...29,987,252
Ensembl chr 6:29,977,797...29,987,451
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity affects binding |
ISO |
[Terfenadine co-treated with dofetilide] binds to and results in decreased activity of KCNH2 protein; Acids inhibits the reaction [dofetilide results in decreased activity of KCNH2 protein]; dofetilide analog inhibits the reaction [Astemizole binds to KCNH2 protein]; dofetilide analog inhibits the reaction [dofetilide binds to KCNH2 protein]; dofetilide binds to and results in decreased activity of KCNH2 protein; dofetilide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; dofetilide promotes the reaction [naringenin results in decreased activity of KCNH2 protein]; Hydrogen Peroxide inhibits the reaction [dofetilide results in decreased activity of KCNH2 protein mutant form]; naringenin promotes the reaction [dofetilide results in decreased activity of KCNH2 protein]; Potassium affects the reaction [dofetilide analog inhibits the reaction [dofetilide binds to KCNH2 protein]]; Potassium inhibits the reaction [dofetilide results in decreased activity of KCNH2 protein]; Potassium promotes the reaction [dofetilide binds to KCNH2 protein] |
CTD |
PMID:9395068 PMID:10828461 PMID:15272206 PMID:15821840 PMID:15961988 PMID:16960444 PMID:17042915 PMID:18057881 PMID:18701618 PMID:20071423 PMID:21158687 PMID:24052561 PMID:24200993 PMID:24830940 PMID:30561737 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
EXP |
dofetilide inhibits the reaction [Isoproterenol results in increased expression of NCF2 mRNA]; dofetilide inhibits the reaction [Isoproterenol results in increased expression of NCF2 protein] |
CTD |
PMID:20723002 |
|
NCBI chr13:70,226,441...70,259,019
Ensembl chr13:70,226,647...70,257,576
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
dofetilide inhibits the reaction [Isoproterenol results in increased expression of PRKCE mRNA]; dofetilide inhibits the reaction [Isoproterenol results in increased expression of PRKCE protein] |
CTD |
PMID:20723002 |
|
NCBI chr 6:9,483,400...9,973,396
Ensembl chr 6:9,790,422...9,973,396
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport affects response to substance decreases expression affects transport affects binding multiple interactions |
ISO |
ABCB1 protein results in increased transport of Quinidine ABCB1A protein affects the susceptibility to Quinidine Quinidine results in decreased expression of ABCB1 protein ABCB1 protein affects the transport of Quinidine Quinidine binds to ABCB1 protein methoxyfenozide inhibits the reaction [ABCB1 protein results in increased transport of Quinidine]; Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Docetaxel]; Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; tebufenozide inhibits the reaction [ABCB1 protein results in increased transport of Quinidine] |
CTD |
PMID:15502009 PMID:15616150 PMID:20196146 PMID:23976943 PMID:26995013 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects response to substance affects activity |
ISO EXP |
ABCB1B protein affects the susceptibility to Quinidine Quinidine affects the activity of ABCB1B protein |
CTD |
PMID:12626638 PMID:15502009 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
EXP |
Quinidine results in decreased expression of ACADM mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
affects binding multiple interactions |
ISO |
Quinidine binds to ADRA1A protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1A protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1A protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
affects binding multiple interactions |
ISO |
Quinidine binds to ADRA1B protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1B protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1B protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
affects binding multiple interactions |
ISO |
Quinidine binds to ADRA1D protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1D protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1D protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr 3:124,129,558...124,145,566
Ensembl chr 3:124,129,558...124,145,566
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Quinidine results in increased expression of ALDOA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Quinidine results in increased expression of ASNS mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Quinidine results in increased expression of CAT protein |
CTD |
PMID:12708743 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Quinidine results in increased expression of CDKN1A protein |
CTD |
PMID:12243503 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
EXP |
Quinidine results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
EXP |
Quinidine results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:124,024,003...124,041,564
Ensembl chr 7:124,023,995...124,041,594
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
Quinidine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Quinidine results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 PMID:18493746 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
Quinidine affects the reaction [CYP1A2 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] Quinidine results in decreased activity of CYP1A2 protein |
CTD |
PMID:15916432 PMID:19053182 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP1B1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity multiple interactions |
EXP ISO |
Quinidine results in decreased activity of CYP2C6V1 protein Quinidine affects the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] |
CTD |
PMID:12814958 PMID:19053182 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2C29 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [CYP2D2 protein results in increased metabolism of 3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin] |
CTD |
PMID:19858067 |
|
NCBI chr 7:123,651,827...123,655,896
Ensembl chr 7:123,651,827...123,655,896
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing decreases activity multiple interactions |
ISO EXP |
CYP2D6 protein results in increased metabolism of Quinidine Quinidine results in decreased activity of CYP2D6 protein [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride Quinidine results in decreased activity of CYP2D6 gene mutant form; Quinidine results in decreased activity of CYP2D6 protein [Quinidine results in decreased activity of CYP2D6 protein] which affects the susceptibility to Oxycodone; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of 4-hydroxy-N-desmethyltamoxifen; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of Aconitine metabolite; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased hydroxylation of N-desmethyltamoxifen; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; Quinidine binds to and results in decreased activity of CYP2D6 protein; Quinidine inhibits the reaction [3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin results in increased metabolism of CYP2D6 protein]; Quinidine inhibits the reaction [[CYP2D6 protein results in increased metabolism of 7-methoxy-4-(aminomethyl)coumarin] which results in increased chemical synthesis of Coumarins]; Quinidine inhibits the reaction [CYP2D6 protein affects the metabolism of 1-(3-chlorophenyl)piperazine]; Quinidine inhibits the reaction [CYP2D6 protein results in increased chemical synthesis of Dextrorphan]; Quinidine inhibits the reaction [CYP2D6 protein results in increased hydrolysis of bufuralol]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of auriculasin]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of bufuralol]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of tegaserod]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of YM 758]; Quinidine inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein] |
CTD |
PMID:8819299 PMID:11377097 PMID:11560869 PMID:11673748 PMID:12464242 PMID:12467917 PMID:12569440 PMID:12814958 PMID:14652237 PMID:15155557 PMID:15306208 PMID:15860655 PMID:16035375 PMID:16595712 PMID:17702393 PMID:18238857 PMID:18420780 PMID:19230594 PMID:19328226 PMID:20345925 PMID:20590588 PMID:20669986 PMID:21277363 PMID:21336516 PMID:21915887 PMID:23850985 PMID:24167220 PMID:26599973 PMID:28119166 PMID:28887089 PMID:31515991 PMID:32198085 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2E1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions affects metabolic processing |
ISO |
Quinidine inhibits the reaction [CYP3A4 protein results in increased metabolism of YM 758]; Quinidine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] CYP3A4 protein affects the metabolism of Quinidine |
CTD |
PMID:2271712 PMID:15784650 PMID:19230594 PMID:19299527 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
increases expression |
ISO |
Quinidine results in increased expression of DEPP1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 4:148,780,330...148,784,566
Ensembl chr 4:148,782,479...148,784,562
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Quinidine results in increased expression of FABP1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
EXP |
Quinidine results in increased expression of FGA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgb |
fibrinogen beta chain |
increases expression |
EXP |
Quinidine results in increased expression of FGB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of GSTM1 protein |
CTD |
PMID:11807801 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases expression |
EXP |
Quinidine results in decreased expression of GSTM3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases activity |
ISO |
Quinidine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid] Quinidine results in decreased activity of GSTP1 protein |
CTD |
PMID:11807801 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
increases expression |
EXP |
Quinidine results in increased expression of HIBADH mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:82,604,369...82,702,429
Ensembl chr 4:82,604,373...82,702,429
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein] |
CTD |
PMID:17520698 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Quinidine results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169
|
|
G |
Kcnh1 |
potassium voltage-gated channel subfamily H member 1 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein] |
CTD |
PMID:17520698 |
|
NCBI chr13:110,920,712...111,232,291
Ensembl chr13:110,920,737...111,232,269
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity affects activity affects binding affects localization affects response to substance decreases response to substance |
ISO |
[Quinidine results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; Acids inhibits the reaction [Quinidine results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [Quinidine results in decreased activity of KCNH2 protein]; Potassium inhibits the reaction [Quinidine results in decreased activity of KCNH2 protein]; Quinidine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Quinidine promotes the reaction [naringenin results in decreased activity of KCNH2 protein] Quinidine affects the activity of KCNH2 protein Quinidine binds to KCNH2 protein Quinidine affects the localization of KCNH2 protein mutant form KCNH2 gene SNP affects the susceptibility to Quinidine KCNH2 gene mutant form results in decreased susceptibility to Quinidine |
CTD |
PMID:11741928 PMID:12695533 PMID:15671647 PMID:15673388 PMID:15821840 PMID:16960444 PMID:17042915 PMID:18057881 PMID:18701618 PMID:18724381 PMID:19583963 PMID:21158687 PMID:21362439 PMID:22020101 PMID:24052561 PMID:28551711 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kcnk1 |
potassium two pore domain channel subfamily K member 1 |
multiple interactions |
ISO |
Quinidine affects the reaction [KCNK1 protein results in increased transport of Potassium]; Quinidine inhibits the reaction [KCNK1 protein results in increased transport of Sodium] |
CTD |
PMID:16847696 |
|
NCBI chr19:58,823,836...58,862,926
Ensembl chr19:58,823,814...58,862,926
|
|
G |
Kcnk18 |
potassium two pore domain channel subfamily K member 18 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [KCNK18 protein results in increased transport of Potassium] |
CTD |
PMID:12754259 |
|
NCBI chr 1:280,383,579...280,397,784
Ensembl chr 1:280,383,579...280,397,784
|
|
G |
Kcnk9 |
potassium two pore domain channel subfamily K member 9 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [KCNK9 protein results in increased transport of Potassium] |
CTD |
PMID:10734076 |
|
NCBI chr 7:113,894,918...113,938,397
Ensembl chr 7:113,903,557...113,937,941
|
|
G |
Lbp |
lipopolysaccharide binding protein |
increases expression |
EXP |
Quinidine results in increased expression of LBP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:154,786,232...154,812,910
Ensembl chr 3:154,786,215...154,813,464
|
|
G |
Lipc |
lipase C, hepatic type |
decreases expression |
EXP |
Quinidine results in decreased expression of LIPC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
Quinidine results in decreased expression of MYC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Quinidine results in increased expression of NUPR1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Otc |
ornithine transcarbamylase |
decreases expression |
EXP |
Quinidine results in decreased expression of OTC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:13,524,804...13,601,074
Ensembl chr X:13,524,607...13,601,069
|
|
G |
Pklr |
pyruvate kinase L/R |
decreases expression |
EXP |
Quinidine results in decreased expression of PKLR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
|
|
G |
Ptma |
prothymosin alpha |
decreases expression |
EXP |
Quinidine results in decreased expression of PTMA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 9:93,545,396...93,549,436
Ensembl chr 9:93,545,396...93,549,436
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
EXP |
Quinidine results in increased expression of S100A9 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
affects response to substance |
ISO |
SCN5A gene mutant form affects the susceptibility to Quinidine |
CTD |
PMID:17805561 |
|
NCBI chr 8:128,169,191...128,266,681
Ensembl chr 8:128,169,191...128,266,639
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
EXP ISO |
[Quinidine analog results in decreased activity of SLC22A1 protein] which results in decreased import of Phenylephrine; [Quinidine analog results in decreased activity of SLC22A1 protein] which results in decreased import of Synephrine Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of Monocrotaline]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of Quercetin]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of retrorsine] |
CTD |
PMID:16141367 PMID:21140131 PMID:23831208 PMID:24799337 PMID:24947867 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:16141367 PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16141367 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
decreases expression |
ISO |
Quinidine results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr 4:155,549,991...155,626,018
Ensembl chr 4:155,408,233...155,631,856
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
decreases activity multiple interactions |
ISO |
Quinidine results in decreased activity of SLC47A1 protein Quinidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16928787 PMID:22419765 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Quinidine results in decreased expression of TAGLN mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
EXP |
Quinidine results in increased expression of TIMP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
decreases expression |
EXP |
Quinidine results in decreased expression of TNFRSF1A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Tnfrsf8 |
TNF receptor superfamily member 8 |
decreases expression |
ISO |
Quinidine results in decreased expression of TNFRSF8 protein |
CTD |
PMID:12441127 |
|
NCBI chr 5:163,186,349...163,231,578
Ensembl chr 5:163,186,349...163,231,578
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
EXP |
Quinidine results in decreased expression of TP53 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity |
ISO |
Tolbutamide inhibits the reaction [ABCB1 protein results in increased uptake of quinidinium] Tolbutamide results in decreased activity of ABCB1 protein |
CTD |
PMID:32305507 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
multiple interactions |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Tolbutamide; ABCC8 gene SNP inhibits the reaction [Tolbutamide results in increased secretion of INS protein]; Tolbutamide inhibits the reaction [ABCC8 protein mutant form results in increased activity of KCNJ11 protein] |
CTD |
PMID:9568693 PMID:18025464 PMID:22209866 |
|
NCBI chr 1:102,110,708...102,191,287
Ensembl chr 1:102,110,708...102,191,287
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Tolbutamide binds to ALB protein |
CTD |
PMID:19596536 PMID:20435530 PMID:20956006 PMID:20974553 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
EXP |
Tolbutamide results in increased expression of CCND1 protein |
CTD |
PMID:16718685 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd3 |
cyclin D3 |
increases expression |
EXP |
Tolbutamide results in increased expression of CCND3 protein |
CTD |
PMID:16718685 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
EXP |
GJA1 promotes the reaction [Tolbutamide results in increased expression of CDKN1A protein] |
CTD |
PMID:16718685 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP |
Tolbutamide results in increased expression of CDKN1B protein |
CTD |
PMID:16718685 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases metabolic processing multiple interactions decreases hydroxylation increases chemical synthesis increases hydroxylation increases metabolic processing affects hydroxylation increases hydrolysis affects metabolic processing |
ISO |
CYP2C9 gene polymorphism results in decreased metabolism of Tolbutamide [CYP2C9 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide; Acetone promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; acetonitrile promotes the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; CYP2C9 gene mutant form inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; CYP2C9 protein binds to and affects the metabolism of Tolbutamide; Fenitrothion inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; Malathion inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; phenthoate inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; pranlukast inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; profenofos inhibits the reaction [CYP2C9 protein results in increased hydroxylation of Tolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased hydrolysis of Tolbutamide]; Sulfaphenazole inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; Ticlopidine inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide]; Tolbutamide inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac]; zafirlukast inhibits the reaction [CYP2C9 protein results in increased metabolism of Tolbutamide] CYP2C9 gene SNP results in decreased hydroxylation of Tolbutamide CYP2C9 protein results in increased chemical synthesis of Tolbutamide metabolite CYP2C9 protein affects the hydroxylation of Tolbutamide CYP2C9 gene polymorphism affects the metabolism of Tolbutamide; CYP2C9 gene SNP affects the metabolism of Tolbutamide; CYP2C9 protein affects the metabolism of Tolbutamide |
CTD |
PMID:2025243 PMID:9110362 PMID:9170147 PMID:9522436 PMID:10208645 PMID:10611138 PMID:11377097 PMID:11875364 PMID:12426520 PMID:12433797 PMID:12464242 PMID:12467917 PMID:15045499 PMID:15155557 PMID:15327588 PMID:15370959 PMID:15626586 PMID:15843491 PMID:15856409 PMID:16081671 PMID:16124035 PMID:17267297 PMID:17565714 PMID:17702393 PMID:19082874 PMID:19715737 PMID:21915887 PMID:22634058 PMID:23850985 PMID:25994031 PMID:26255664 PMID:26763401 PMID:32198085 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
increases metabolic processing multiple interactions |
ISO |
CYP2C18 results in increased metabolism of Tolbutamide [CYP2C55 protein results in increased metabolism of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:15301741 PMID:30503582 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases metabolic processing multiple interactions increases hydroxylation |
ISO |
CYP2C19 protein results in increased metabolism of Tolbutamide [CYP2C19 protein results in increased hydroxylation of Tolbutamide] which results in increased chemical synthesis of 4'-hydroxytolbutamide |
CTD |
PMID:18511451 PMID:30500380 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases hydroxylation |
ISO |
CYP2C8 protein results in increased hydroxylation of Tolbutamide |
CTD |
PMID:15843491 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Gcg |
glucagon |
increases secretion |
EXP |
Tolbutamide results in increased secretion of GCG protein |
CTD |
PMID:15919803 |
|
NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions increases expression |
EXP |
GJA1 promotes the reaction [Tolbutamide results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] Tolbutamide results in increased expression of GJA1 protein |
CTD |
PMID:11741589 PMID:16718685 |
|
NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
|
|
G |
Hk1 |
hexokinase 1 |
increases expression |
ISO |
Tolbutamide results in increased expression of HK1 protein |
CTD |
PMID:11835228 |
|
NCBI chr20:31,911,460...31,979,780
Ensembl chr20:31,912,262...31,956,649
|
|
G |
Ins2 |
insulin 2 |
multiple interactions increases secretion |
ISO |
ABCC8 gene SNP inhibits the reaction [Tolbutamide results in increased secretion of INS protein] |
CTD |
PMID:9032110 PMID:9568693 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions decreases activity |
ISO |
[KCNJ11 mutant form co-treated with ABCC8 mutant form] results in decreased susceptibility to Tolbutamide; Tolbutamide inhibits the reaction [ABCC8 protein mutant form results in increased activity of KCNJ11 protein] Tolbutamide results in decreased activity of KCNJ11 protein |
CTD |
PMID:18025464 PMID:22209866 |
|
NCBI chr 1:102,103,093...102,107,134
Ensembl chr 1:102,103,094...102,106,127
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Tolbutamide results in decreased expression of MKI67 protein |
CTD |
PMID:16718685 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Pdcd4 |
programmed cell death 4 |
decreases expression increases expression |
ISO |
Tolbutamide results in decreased expression of PDCD4 mRNA Tolbutamide results in increased expression of PDCD4 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
EXP |
Tolbutamide results in decreased phosphorylation of RB1 protein |
CTD |
PMID:16718685 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases expression |
ISO |
Tolbutamide results in increased expression of SLC2A1 mRNA; Tolbutamide results in increased expression of SLC2A1 protein |
CTD |
PMID:2682625 PMID:11835228 |
|
NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
decreases expression |
ISO |
Tolbutamide results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
EXP |
Tolbutamide results in increased expression of TP53 mRNA |
CTD |
PMID:16426753 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tpd52 |
tumor protein D52 |
decreases expression increases expression |
ISO |
Tolbutamide results in decreased expression of TPD52 mRNA Tolbutamide results in increased expression of TPD52 mRNA |
CTD |
PMID:21873647 |
|
NCBI chr 2:94,959,732...95,041,277
Ensembl chr 2:95,008,311...95,040,514
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
decreases expression |
EXP |
Tolbutamide results in decreased expression of UGDH protein |
CTD |
PMID:4270849 |
|
NCBI chr14:44,479,614...44,502,845
Ensembl chr14:44,479,614...44,502,845
|
|
|
G |
Agt |
angiotensinogen |
increases expression |
EXP |
Torsemide results in increased expression of AGT protein modified form |
CTD |
PMID:18154949 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
affects expression |
EXP |
Torsemide affects the expression of CYP11B2 protein |
CTD |
PMID:18001696 |
|
NCBI chr 7:116,155,928...116,161,781
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
affects metabolic processing increases metabolic processing increases hydroxylation |
EXP ISO |
CYP2C11 protein affects the metabolism of Torsemide CYP2C9 protein results in increased metabolism of Torsemide CYP2C9 protein results in increased hydroxylation of Torsemide |
CTD |
PMID:9110362 PMID:15890479 PMID:19082874 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases metabolic processing multiple interactions |
ISO |
CYP2C8 protein results in increased metabolism of Torsemide Torsemide inhibits the reaction [Amiodarone results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Fluoxetine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Nortriptyline results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Phenelzine results in decreased activity of CYP2C8 protein]; Torsemide inhibits the reaction [Verapamil results in decreased activity of CYP2C8 protein] |
CTD |
PMID:15304522 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
EXP |
Torsemide results in decreased expression of NPPA protein |
CTD |
PMID:18154949 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
EXP |
Torsemide inhibits the reaction [Aldosterone binds to NR3C2 protein] |
CTD |
PMID:7954537 |
|
NCBI chr19:34,408,275...34,761,003
Ensembl chr19:34,448,289...34,752,695
|
|
G |
Ren |
renin |
increases expression |
EXP |
Torsemide results in increased expression of REN protein |
CTD |
PMID:7954537 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
decreases activity multiple interactions |
ISO |
Torsemide results in decreased activity of SLC12A2 protein Torsemide inhibits the reaction [SLC12A2 protein results in increased uptake of Rubidium] |
CTD |
PMID:29959396 |
|
NCBI chr18:52,917,124...52,985,281
Ensembl chr18:52,917,124...52,985,261
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression affects expression |
EXP |
Torsemide results in decreased expression of TGFB1 protein Torsemide affects the expression of TGFB1 protein |
CTD |
PMID:18001696 PMID:18154949 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|